Treatment
Ipilimumab clinical trials
We’re tracking 122 recruiting studies that include Ipilimumab, each written for real people, not researchers, below.
Recruiting studies
- NCT06999980RecruitingPhase 2
NEOadjuvant Ipi Nivo Rela for Melanoma
This trial tests a combination of three immunotherapy drugs (ipilimumab, relatlimab, and nivolumab) given before surgery to people with melanoma that can be completely removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Wollstonecraft, New South WalesAges 18 years+ - NCT07643623RecruitingPhase 2/Phase 3
Immunotherapy for operable stomach cancer before and after surgery
This trial tests a combination of immunotherapy drugs (sintilimab, chemotherapy, and sometimes ipilimumab) given before surgery to shrink stomach or esophageal junction tumors, then continued after surgery. The goal is to improve survival in patients with resectable (removable) gastric or gastroesophageal junction cancer.
Guangzhou, GuangdongAges 18 years+ - NCT07188896RecruitingPhase 2
Immunotherapy combinations for advanced kidney cancer
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06708949RecruitingPhase 2
Immunotherapy combo for advanced kidney cancer
This trial compares two immunotherapy combinations—nivolumab/relatlimab/ipilimumab vs. nivolumab/ipilimumab—as first treatment for advanced kidney cancer with clear cell features. It aims to see which combo works better for people who haven't had prior therapy.
Boston, MassachusettsAges 18 years+ - NCT07506109RecruitingPhase 2
Study of sintilimab, ipilimumab, cetuximab, and dabrafenib for advanced colorectal cancer
This trial tests a combination of four drugs for people with a specific type of advanced colorectal cancer that has a BRAF V600E mutation and is microsatellite stable. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06683755RecruitingPhase 1/Phase 2
Triple immunotherapy for first-line metastatic melanoma
This trial tests a combination of three immune-boosting drugs (relatlimab, ipilimumab, and nivolumab) as the first treatment for melanoma that has spread. The goal is to see if this triple therapy is safe and works better than current options.
Houston, TexasAges 18 years+ - NCT07504796RecruitingPhase 2
Adding ipilimumab to standard melanoma therapy based on ctDNA
This trial tests whether adding a second immunotherapy drug (ipilimumab) to the standard first-line combo of nivolumab and relatlimab improves outcomes for advanced melanoma. It uses a blood test (ctDNA) to decide who gets the extra drug.
New York, New YorkAges 18 years+ - NCT04933903RecruitingPhase 2
Neoadjuvant low-dose radiation plus immunotherapy before lung surgery
This trial tests whether giving low-dose focused radiation and two immunotherapy drugs before lung surgery can improve outcomes for people with operable, resectable non-small cell lung cancer. It aims to shrink or control the cancer before surgery and help reduce the chance it comes back.
Providence, Rhode IslandAges 18 years+ - NCT07291076RecruitingPhase 1/Phase 2
Study of Pumitamig with Ipilimumab for first-line advanced liver cancer
This trial tests a new drug called pumitamig, either alone or with another drug (ipilimumab), for people with advanced liver cancer that hasn't been treated yet. The goal is to see if these drugs can help shrink or control the cancer.
Duarte, CaliforniaAges 18 years+ - NCT07444619RecruitingPhase 1
Combination drugs for returning soft tissue sarcoma in young people
This trial tests if combining four drugs (pazopanib, trabectedin, ipilimumab, and nivolumab) can help treat soft tissue sarcomas that have come back. It is for children and young adults up to age 30.
Houston, TexasAges 1–30 - NCT04248569RecruitingPhase 1
Vaccine plus immunotherapy for a specific liver cancer gene change
This Phase 1 trial tests a personalized peptide vaccine (targeting the DNAJB1-PRKACA fusion) combined with immunotherapy drugs to treat fibrolamellar hepatocellular carcinoma (FLC) or other eligible non-FLC cancers with the same gene fusion. It aims to see whether this immune-based treatment can shrink tumors and improve outcomes safely.
Baltimore, MarylandAges 12 years+ - NCT06747845RecruitingPhase 2
Maintenance therapy for stable metastatic pancreatic cancer
This trial tests a combination of two drugs, niraparib and ipilimumab, as a maintenance treatment for people with metastatic pancreatic cancer that has not grown after initial chemotherapy. The goal is to see if this can help keep the cancer stable longer.
Boston, MassachusettsAges 18 years+ - NCT03707808RecruitingPhase 1/Phase 2
Study drugs into a tumor plus immune therapy for advanced cancer
This trial tests injecting an immune-boosting mixture directly into a skin or lymph node tumor, along with immune-checkpoint medicines given through the vein. It aims to help the body recognize and fight advanced cancers that can’t be fully removed by surgery.
Jette, BrabantAges 18 years+ - NCT06594991RecruitingPhase 2
A study of three immunotherapy drugs for advanced melanoma
This trial tests a combination of three immunotherapy drugs (fianlimab, cemiplimab, and ipilimumab) for people with advanced melanoma that has stopped responding to previous PD-1/PD-L1 treatment. It aims to see if this new combination can help shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07061379Recruiting
Patient feedback in first-line lung cancer treatment study
This study collects patient feedback through questionnaires to see if it helps improve outcomes for people with advanced non-small-cell lung cancer starting chemo-immunotherapy. It may help your care team better understand how you are feeling.
Milan, ItalyAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Birmingham, AlabamaAges 18 years+ - NCT05112601RecruitingPhase 2
Nivolumab plus or minus ipilimumab for dMMR endometrial cancer
This Phase 2 study tests the medicines nivolumab (with or without ipilimumab) in people with recurrent endometrial cancer that has “dMMR” (a specific tumor DNA repair defect). It aims to see whether this immune-based treatment can shrink tumors or help them stop growing.
Birmingham, AlabamaAges 18 years+ - NCT07293351RecruitingPhase 1/Phase 2
Testing pumitamig with other drugs for advanced kidney cancer
This study tests a new drug (pumitamig) alone or with ipilimumab or cabozantinib for advanced kidney cancer that cannot be removed by surgery. It aims to find effective treatment options for people whose cancer has spread or is locally advanced.
Palo Alto, CaliforniaAges 18 years+ - NCT03521830RecruitingPhase 2
Nivolumab and other immunotherapy for advanced basal cell skin cancer
This study tests how well the immunotherapy medicine nivolumab works—either by itself or combined with other immune-boosting drugs—for people with advanced basal cell carcinoma that can’t be removed by surgery or has spread. It’s also looking at what to do if the cancer grows again after an earlier immunotherapy.
Baltimore, MarylandAges 18 years+ - NCT03844256RecruitingPhase 1/Phase 2
Bladder-sparing chemo-radiation plus immunotherapy for bladder cancer
This study tests whether adding immunotherapy drugs (nivolumab alone or nivolumab plus ipilimumab) to standard chemo-radiation can control muscle-invasive bladder cancer while helping people keep their bladder. It aims to find a safer, effective curative treatment for people who want to avoid bladder removal (cystectomy).
Amsterdam, North HollandAges 18 years+ - NCT04511013RecruitingPhase 2
Trial for BRAF-mutant melanoma spread to the brain
This Phase 2 study tests whether a 3-drug plan (encorafenib + binimetinib + nivolumab) works better than ipilimumab + nivolumab for melanoma that has spread to the brain. If you qualify, you’ll get either treatment and have frequent brain scans to track how well it controls the tumors.
Birmingham, AlabamaAges 18 years+ - NCT04562129RecruitingPhase 2
IL-2 then ipilimumab followed by nivolumab for advanced melanoma
This Phase 2 trial studies a specific sequence of immune medicines for people with stage 3 or 4 melanoma that has spread or cannot be removed. It’s designed for melanoma that worsened after prior PD-1 treatment, aiming to shrink tumors and control disease.
Tampa, FloridaAges 18 years+ - NCT04823403RecruitingPhase 1
Targeted liver delivery of immunotherapy for advanced liver cancer
This early-phase study tests how well giving ipilimumab directly into the liver (via an artery) and nivolumab through a vein works for advanced hepatocellular carcinoma (liver cancer). It is for people whose cancer cannot be removed with surgery or treated with a transplant, especially after standard treatment failed or wasn’t tolerated.
VillejuifAges 18 years+ - NCT05048212RecruitingPhase 2
Nivolumab, ipilimumab, and cabozantinib for kidney cancer brain spread
This Phase 2 study tests how well nivolumab plus ipilimumab, along with cabozantinib, treats untreated or worsening kidney cancer that has spread to the brain. It may help shrink brain tumors and slow the disease when standard local brain treatments aren’t the right option.
Houston, TexasAges 18 years+
What Ipilimumab is being studied for
Conditions with recruiting Ipilimumab studies.
Common questions
- Are there clinical trials studying Ipilimumab?
- Yes. Clin2 currently lists 122 recruiting studies that include Ipilimumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Ipilimumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Ipilimumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Ipilimumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.